Mr. Hugh MacNaught reports

VENTRIPOINT ANNOUNCES EXTENSION AND UP SIZE OF NON-BROKERED CONVERTIBLE DEBENTURE UNIT PRIVATE PLACEMENT

Ventripoint Diagnostics Ltd. will seek approval of TSX Venture Exchange to extend its previously announced non-brokered private placement of unsecured convertible debentures to Nov. 2, 2025 (see news releases dated Aug. 26, 2025, and Sept. 3, 2025).

Ventripoint will also seek approval of the TSX-V to increase the size of the offering from $500,000 to $560,000.

Each unit comprises: one unsecured convertible debenture principal amount of $1,000 convertible into common shares of the corporation; and 9,000 common share purchase warrants.

The debentures are convertible into common shares of the corporation at the option of the holder at any time prior to maturity at a conversion price of 11 cents per common share. Each whole warrant will entitle the holder thereof to purchase one common share at a price of 14 cents until Dec. 31, 2027.

The debentures mature Dec. 31, 2027, and bear interest at the rate of 10 per cent, payable semi-annually in arrears in either cash or, at the option of the corporation, by the issuance of common shares at a 20-day VWAP (volume-weighted average price), determined at time of payment, subject to exchange approval.

The corporation will use the proceeds of the offering to finance operational costs related sales and marketing, additional key personnel, and general working capital purposes.

All securities issued and issuable pursuant to the offering are subject to a hold period of four months plus one day from the date of closing of the offering. The offering is subject to final approval by the exchange.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS+ products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.